Monday, Nov. 13, Catalent will host a “Lunch and Learn” session at 12 p.m., entitled, Drug Delivery 2017: The Path Ahead. Cornell Stamoran, Ph.D., founder and co-chair of the Catalent Applied Drug Delivery Institute and VP Corporate Strategy, and Ronak Savla, Pharm.D., Ph.D., Scientific Affairs Manager, will moderate discussions on current and future drug delivery trends.
 
Monday, Nov. 13, 2:00 p.m., Catalent will present a symposium entitled Patient Focused Drug Design, including an overview of patient and stakeholder needs, discussion of strategies to incorporate these considerations at the formulation stage, and why these approaches make good business sense. Presentations will be given by Cornell Stamoran and Stephen Tindal of Catalent, joined by drug delivery experts Dr. Keith Horspool and Dr. Ralph Niven, and Mike Rea, Chief Executive Officer of IDEA Pharma.
 
Monday, Nov. 13, 4:00 p.m., Julien Meissonnier, Vice President, Science & Technology, will present Formulation Approaches to Enhance Bioavailability of Oral Anticancer Drugs. The presentation will discuss how many targeted small molecule drugs for oncology treatments carry black box warnings on their labels, and how formulation can overcome the biopharmaceutical and pharmacokinetic challenges of oral anticancer drugs, and lead to better patient outcomes.
 
Tuesday, Nov. 14, 1:00 p.m., Catalent will host a two-part workshop starting at 1 p.m., entitled, Start Earlier, Move Faster: Smart Drug Development & Design from Candidate to Phase I. Several speakers will present on a range of topics focusing on the transition of a molecule from discovery to phase I readiness. The interactive workshop includes case studies that will ask the audience to work in teams to develop solutions. Part one will provide an overview of the state of the industry and the tools and techniques used to characterize and assess an API molecule; and part two will give the audience the opportunity to learn strategies for enhancing API bioavailability during preclinical stages and getting into early clinical studies. Edward Narke, Principal at DSI InPharmatics will be joining Catalent to present.
 
Catalent will also present 26 scientific posters at AAPS meeting on a wide range of topics. A full list of poster topics and presentation times can be found at catalent.com/AAPS